News and Information

Manuscripts

  1. D'Amico, L., W. L. Seng, et al. (2012). "Assessment of drug-induced cardiotoxicity in zebrafish. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 45-54.
  2. D'Amico, L., C. Li, et al. (2012). "Zebrafish: a predictive model for assessing cancer drug-induced organ toxicity. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 135-149.
  3. Haldi, M., M. Harden, et al. (2012). "Developmental toxicity assessment in zebrafish. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 15-25.
  4. Li, C., L. Luo, et al. (2012). "Whole zebrafish cytochrome P450 assay for assessing drug metabolism and safety. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 103-115.
  5. Li, C., W. L. Seng, et al. (2012). "Methods for assessing neurotoxicity in zebrafish. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ."117-134.
  6. Li. C., L. Luo, et al. (2012). "Zebrafish xenotransplant cancer model for drug screening. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 219-232.
  7. McGrath, P. (2012). "Use of emerging models for developmental toxicity testing. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 27-44.
  8. Park, D., J. Meidenbauer, et al. (2012). "Zebrafish: a predictive model for assessing seizure liability. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 165-175.
  9. Park, D., M. Haldi, et al. (2012). "Zebrafish: A new in vivo model for identifying P-glycoprotein efflux modulators. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 177-190.
  10. Seng, W. L., Y. Lin, et al. (2012). "Development of a hypoxia-induced zebrafish choroidal neovascularization model. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 205-218.
  11. Tang, J., S. Tang, et al. (2012). "Zebrafish assays for identifying potential muscular dystrophy drug candidates. McGrath (ed) "Zebrafish, methods for assessing drug safety and toxicity". John Wiley & Sons, Inc., Hoboken, NJ." 233-256.
  12. McGrath, P. and C. Q. Li (2008). "Zebrafish: a predictive model for assessing drug-induced toxicity." Drug Discov. Today 13(9-10): 394-401.
  13. Beuerle, F., P. Witte, et al. (2007). "Cytoprotective activities of water-soluble fullerenes in zebrafish models." J Exp Nanosci 2(3): 147-70.
  14. Parng, C., N. M. Roy, et al. (2007). "Neurotoxicity assessment using zebrafish." J Pharmacol Toxicol Methods 55(1): 103-112.
  15. Haldi, M., C. Ton, et al. (2006). "Human melanoma cells transplanted into zebrafish proliferate, migrate, produce melanin, form masses and stimulate angiogenesis in zebrafish.Angiogenesis 9(3): 139-151.
  16. Ton, C., Y. Lin, et al. (2006). "Zebrafish as a model for developmental neurotoxicity testing.Birth Defects Res A Clin Mol Teratol 76(7): 553-67.
  17. Parng, C., C. Ton, et al. (2006). "A zebrafish assay for identifying neuroprotectants in vivo." Neurotoxicol Teratol 28(4): 509-16.
  18. Ton, C. and C. Parng (2005). "The use of zebrafish for assessing ototoxic and otoprotective agents."  Hear Res 208(1-2): 79-88.
  19. Parng, C. (2005). "In vivo zebrafish assays for toxicity testing." Curr Opin Drug Discov Devel 8(1): 100-106.
  20. Seng, W. L., K. Eng, et al. (2004). "Use of a monoclonal antibody specific for activated endothelial cells to quantitate angiogenesis in vivo in zebrafish after drug treatment."Angiogenesis 7(3): 243-53.
  21. Ma, C. (2004). "Animal models of disease." Modern Drug Discovery: 30-36.
  22. Parng, C., N. Anderson, et al. (2004). "Zebrafish apoptosis assay for drug discovery." Methods Cell Biol 76: 75-85.
  23. Ma, C., C. Parng, et al. (2003). "Zebrafish: An in vivo model for drug screening." Innovations in Pharmaceutical Technologies: 38-45.
  24. Zhang, C., C. Willett, et al. (2003). "Zebrafish: An animal model for toxicological studies." Current Protocols in Toxicology (1.7.1-1.7.18)
  25. Seng, W. L. and P. McGrath (2002). "A high throughput in vivo zebrafish angiogenesis assay." Drug Plus International 1(2): 22-24.
  26. Parng, C., W. L. Seng, et al. (2002). "Zebrafish: A preclinical model for drug screening." Assay Drug Dev Technol 1(1 Pt 1): 41-8.
  27. Seberdzija, G., E. Flynn, et al. (2000). "Zebrafish angiogenesis: A new model for drug screening." Angiogenesis 3(4): 353-359.

Abstracts

  1. Li CQ, Luo LQ, Tang J, Tang S, Seng WL. Zebrafish xenotransplant colon cancer model for drug screening (abstract 2340). Proceedings of the 100th AACR annual meeting, Denver, CO, 2009, P. 567
  2. Haldi M, Luo LQ, Tang J, Li CQ, Seng WL. Zebrafish orthotopic brain cancer model for drug screening (abstract 2322). 100th AACR annual meeting, Denver, CO, 2009, P. 562
  3. Assessment of Ototoxicity and Otoprotection in a Zebrafish Hair Cell Model. W. L. Seng, I. Ezedi, M. Haldi, and P. McGrath. Society of Toxicology 2009
  4. Whole zebrafish cytochrome p450 microplate assays for assessing drug metabolism and drug safety C.Q. Li, W. L. Seng and P. McGrath. Safety Pharmacology Society 2008
  5. Assessment of drug-induced proarrhythmia in adult zebrafish. D. Park, W. L. Seng, C.Q. Li, X. Tang, L. J. D’Amico, P. McGrath. Safety Pharmacology Society 2008
  6. Zebrafish: a predictive model for assessing drug-induced cardiotoxicity. L. J D’Amico, Ph.D., W.L. Seng, Ph.D., Y.Yang, Ph.D., W. Suter, Ph.D. and P. McGrath. Phylonix Pharmaceuticals, Cambridge, MA Novartis Pharmaceuticals, East Hanover, NJ Safety Pharmacology Society 2008
  7. Developmental neurotoxicity assessment in zebrafish: a survey of 200 environmental toxicants. L. J. D’Amico, C.Q Li, W. L. Seng, P. McGrath. Society of Toxicology 2008
  8. Chemicals induce developmental neurotoxicity in zebrafish. C. Q. Li, L. J. D’Amico, W. L. Seng, P. McGrath. American College of Toxicology 2007
  9. In vivo assessment of drug effects on zebrafish liver and kidney. C. Q. Li, L.J. D’Amico, W. L. Seng, P. McGrath. American College of Toxicology 2007
  10. Assessment of compound induced heart, gastrointestinal tract, liver, and kidney toxicity in zebrafish. P. McGrath.1, C.Parng 1, K.A. Augustine 2, W. L. Seng 1, Phylonix, Cambridge, MA 1 Bristol-Myers Squibb 2 Pharmaceutical Research Institute, Department of Reproductive Toxicology, Hopewell, New Jersey. Society of Toxicology 2007
  11. Assessment of drug effects on cardiac repolarization in adult zebrafish by ECG. W. L. Seng, C. Parng, P. McGrath. Society of Toxicology 2007
  12. Zebrafish: a new animal model for identifying drugs that inhibit choroidal neovascularization. L. Zhong, P. McGrath, W.L. Seng. Association of Research in Vision and Ophthalmology 2007
  13. Assessment of drug effects on cardiac functions, including QT prolongation using zebrafish. D. Park, W. L. Seng, C. Q. Li, P. McGrath, X. Tang. International Congress of Toxicology 2007
  14. Chemical exposure induces developmental neurotoxicity in zebrafish. C. Q. Li, L. J. D’Amico, W. L. Seng, P. McGrath. International Congress of Toxicology 2007
  15. Zebrafish: a good model for assessing drug effects on the gastrointestinal system and kidney. W. L. Seng , C. Q. Li, D. Park, P. McGrath. International Congress of Toxicology 2007
<<Back to Home Page